Expression of miRNA in 5-FU resistant esophageal cancer

被引:9
|
作者
Mahawongkajit, Prasit [1 ]
Tomtitchong, Prakitpunthu [1 ]
机构
[1] Thammasat Univ, Fac Med, Dept Surg, Rangsit Campus,99-209 Moo 18,Paholyothin Rd, Amphur Klongluang 12120, Pathumthani, Thailand
关键词
microRNA; 5-FU resistant; esophageal squamous carcinoma cell; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR; NEOADJUVANT; MICRORNAS; SURVIVAL; SURGERY; ADENOCARCINOMA; POLYMORPHISM; OXALIPLATIN; CISPLATIN;
D O I
10.3892/mco.2020.2070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluoropyrimidine plus platinum (FP) are chemotherapeutic drugs that are most frequently used to treat esophageal squamous cell carcinoma (ESCC). However, drug resistance often occurs, and the mechanisms of resistance to 5-FU is yet to be determined. The role of micro (mi)RNAs has been well established in a variety of human cancers. The aim of the present study was to investigate the expression profile of ESCC, revealing the differential expression between ESCC and 5-FU resistant ESCC. The establishment of a 5-FU resistant (5-FUR) cell lines model provides a way of analyzing the expression of miRNAs in drug resistance. The miRNA expression indicated 50 miRNAs that were upregulated in TE10-5-FUR compared with TE10, while 119 miRNAs were downregulated. The TE11-5-FUR demonstrated 140 miRNAs were upregulated compared with TE11, which exhibited 12 downregulated miRNAs. Both cell lines share the 2 candidate upregulated miRNAs (miR-146a and miR-483-5p) and 5 downregulated miRNAs (miR-34a, miR-141, miR-200b, miR-200c and miR-205). Further studies are required to analyze and evaluate the function of the miRNAs.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [41] Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo
    Xie, Qi
    Wu, Min-Yi
    Zhang, Ding-Xuan
    Yang, Yi-Ming
    Wang, Bao-Shuai
    Zhang, Jing
    Xu, Jin
    Zhong, Wei-De
    Hu, Jia-Ni
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (32) : 7342 - 7352
  • [42] Establishment of 5-FU resistant colon cancer cell lines in vivo, and identification of resistant-related miRNAs
    Nakagawa, Yoshihito
    Akao, Yukihiro
    [J]. CANCER SCIENCE, 2018, 109 : 599 - 599
  • [43] Effects of 5-FU
    Wigmore, Peter M.
    Mustafa, Sarah
    El-Beltagy, Maha
    Lyons, Laura
    Umka, Jariya
    Bennett, Geoff
    [J]. CHEMO FOG: CANCER CHEMOTHERAPY-RELATED COGNITIVE IMPARIMENT, 2010, 678 : 157 - 164
  • [44] 5-FU CARDIOTOXICITY
    SANANI, S
    SPAULDING, MB
    MASUD, ARZ
    CANTY, R
    [J]. CANCER TREATMENT REPORTS, 1981, 65 (11-1): : 1123 - 1125
  • [45] Prodrugs of 5-FU
    Kaye, SB
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 23 - 23
  • [46] The cost of 5-FU
    Ryan, RF
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2001, 107 (06) : 1613 - 1613
  • [47] COMPARISON OF TREATMENT OF METASTATIC GASTROINTESTINAL CANCER WITH 5-FLUOROURACIL (5-FU) TO A COMBINATION OF 5-FU WITH CYTOSINE-ARABINOSIDE
    GAILANI, S
    HOLLAND, JF
    BURNINGHAM, R
    LEONE, L
    LARSEN, V
    FALKSON, G
    [J]. CANCER, 1972, 29 (05) : 1308 - +
  • [48] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [49] 5-FU: finally!
    Robert, Jacques
    [J]. BULLETIN DU CANCER, 2019, 106 (03) : 173 - 174
  • [50] Whole transcriptome sequence data of 5-FU sensitive and 5-FU resistant tumors generated in a mouse model of de novo carcinogenesis
    Iacovides, Demetris
    Loizides, Charalambos
    Mitsis, Georgios
    Strati, Katerina
    [J]. DATA IN BRIEF, 2018, 20 : 1602 - 1606